Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 13 of 13 publications.

Van Scoy LJ, Snyder B, Miller EL, Toyobo O, Grewel A, Ha G, Gillespie S, Patel M, Reilly J, Zgierska AE, Lennon RP. Public anxiety and distrust due to perceived politicization and media sensationalism during early COVID-19 media messaging. J Commun Healthc. 2021 Jul 31;14(3):193-205. doi: 10.1080/17538068.2021.1953934

Harries M, Mohr P, Grange F, Ehness R, Benjamin L, Siakpere O, Barth J, Stapelkamp C, Pfersch S, McLeod L, Wolowacz S, Kaye JA, Kontoudis I. Treatment patterns and outcomes of Stage IIIB/IIIC melanoma in France, Germany and the UK: a retrospective and prospective observational study (MELABIS). Int J Clin Pract. 2017 May 16;71(5):e12946. doi: 10.1111/ijcp.12946

Ford LB, Matz J, Hankinson T, Prillaman B, Georges G. A comparison of fluticasone propionate nasal spray and cetirizine in ragweed fall seasonal allergic rhinitis. Allergy Asthma Proc. 2015 Jul;36(4):313-9. doi: 10.2500/aap.2015.36.3860

White MV, Hogue SL, Bennett ME, Goss D, Millar K, Hollis K, Siegel PH, Wolf RA, Wooddell M, Silvia S. EpiPen4Schools pilot survey: occurrence of anaphylaxis, triggers, and epinephrine administration in a U.S. school setting. Allergy Asthma Proc. 2015 Jul;36(4):306-12. doi: 10.2500/aap.2015.36.3859

Hirsch JD, Gnanasakthy A, Lale R, Choi K, Sarkin AJ. Efficacy of canakinumab vs. triamcinolone acetonide according to multiple gouty arthritis-related health outcomes measures. Int J Clin Pract. 2014 Dec;68(12):1503-7. doi: 10.1111/ijcp.12521

Katial RK, Oppenheimer JJ, Ostrom NK, Mosnaim GS, Yancey SW, Waitkus-Edwards KR, Prillaman BA, Ortega HG. Adding montelukast to fluticasone propionate/salmeterol for control of asthma and seasonal allergic rhinitis. Allergy Asthma Proc. 2010 Jan;31(1):68-75. doi: 10.2500/aap.2010.31.3306

Andrews CP, Martin BG, Jacobs RL, Mohar DE, Diaz JD, Amar NJ, Kaiser HB, Vandewalker ML, Bernstein J, Toler WT, Prillaman BA, Dalal AA, Lee LA, Philpot EE. Fluticasone furoate nasal spray is more effective than fexofenadine for nighttime symptoms of seasonal allergy. Allergy Asthma Proc. 2009 Mar;30(2):128-38. doi: 10.2500/aap.2009.30.3204

Naslund MJ, Gilsenan AW, Midkiff KD, Bown A, Wolford ET, Wang A. Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting. Int J Clin Pract. 2007 Sep 1;61(9):1437-45.

Berger A, Dukes E, Martin SA, Edelsberg J, Oster G. Characteristics and healthcare costs of patients with FMS. Int J Clin Pract. 2007 Sep 1;61(9):1498-508.

Santanello NC, DeMuro-Mercon CJ, Shah SR, Schenkel EJ, Ratner PH, Norquist JM, Philip G. Validation of the nighttime symptoms score as a clinically relevant measure of allergic rhinitis. Allergy Asthma Proc. 2006 May 1;27(3):231-9.

Sheth KK, Cook CK, Philpot EE, Prillaman BA, Witham LA, Faris MA, Klein KC, Rickard KA. Concurrent use of intranasal and orally inhaled fluticasone propionate does not affect hypothalamic-pituitary-adrenal-axis function. Allergy Asthma Proc. 2004 Mar;25(2):115-20.

Allen DB, Meltzer EO, Lemanske, Jr. RF, Philpot EE, Faris MA, Kral KM, Prillaman BA, Rickard KA. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc. 2002 Nov;23(6):407-13.

Ratner PH, Howland, 3rd WC, Jacobs RL, Reed KD, Goode-Sellers ST, Prillaman BA, Philpot EE, Cook CK. Relief of sinus pain and pressure with fluticasone propionate aqueous nasal spray: a placebo-controlled trial in patients with allergic rhinitis. Allergy Asthma Proc. 2002 Jul;23(4):259-63.